These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27644904)

  • 21. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction.
    Hulscher JB; van Lanschot JJ
    Dig Surg; 2005; 22(3):130-4. PubMed ID: 15942237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
    Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
    Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials.
    Franco P; Arcadipane F; Strignano P; Spadi R; Trino E; Martini S; Iorio GC; Satolli MA; Airoldi M; Romagnoli R; Camandona M; Ricardi U
    Med Oncol; 2017 Mar; 34(3):40. PubMed ID: 28176241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction.
    Kofoed SC; Muhic A; Baeksgaard L; Jendresen M; Gustafsen J; Holm J; Bardram L; Brandt B; Brenø J; Svendsen LB
    Scand J Surg; 2012; 101(1):26-31. PubMed ID: 22414465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
    Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
    Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis.
    Montagnani F; Fornaro L; Frumento P; Vivaldi C; Falcone A; Fioretto L
    Crit Rev Oncol Hematol; 2017 Jun; 114():24-32. PubMed ID: 28477744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopic ultrasound in the staging of tumours of the oesophagus and gastro-oesophageal junction.
    Richards DG; Brown TH; Manson JM
    Ann R Coll Surg Engl; 2000 Sep; 82(5):311-7. PubMed ID: 11041028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
    Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
    Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
    Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
    J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus.
    Bass GA; Furlong H; O'Sullivan KE; Hennessy TP; Walsh TN
    Eur J Cancer; 2014 Apr; 50(6):1065-75. PubMed ID: 24480403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemoradiotherapy with Volumetric-modulated Arc Therapy for Medium-distal Oesophageal and Gastro-oesophageal Junction Carcinoma.
    Tozzi A; Iftode C; Cozzi L; Ascolese AM; Battista S; Cavina R; Clerici E; Comito T; D'Agostino GR; De Rose F; Franzese C; Garassino I; Romario UF; Navarria P; Rosati R; Spaggiari P; Tomatis S; Scorsetti M
    Anticancer Res; 2015 Jul; 35(7):4109-16. PubMed ID: 26124363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
    Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
    Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time trends and pathological profile of carcinoma lower oesophagus and gastro-oesophageal junction over the last 20 years--an experience from South India.
    Tony J; Kumar SK; Thomas V
    Trop Gastroenterol; 2007; 28(3):113-6. PubMed ID: 18383999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.